This trial is evaluating whether Pembrolizumab will improve 1 primary outcome and 10 secondary outcomes in patients with Metastatic Colorectal Cancer (CRC). Measurement will happen over the course of At 6 Months.
This trial requires 78 total participants across 3 different treatment groups
This trial involves 3 different treatments. Pembrolizumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Results from a recent paper suggests some factors associated with the occurrence of colorectal cancer and can be used as an indicator for the development of colorectal cancer." - Anonymous Online Contributor
"Colonoscopy with a biopsy is the gold standard for the diagnosis of colorectal cancer. The presence of symptoms does not necessarily affect the type of procedure done as a prelude to colonoscopy. If symptoms indicate a colonoscopy, then fecal occult blood testing should always be completed. If results are positive, then a colonoscopy is recommended, with biopsy if indicated by a positive result. If this is negative, then screening with colonoscopy without a biopsy is appropriate, because a positive FOBT result is a poor predictor of finding colorectal cancer at colonoscopy." - Anonymous Online Contributor
"A clinical history will always be of paramount importance in the investigation of cases of colorectal cancer. The main physical features of the patient are: the type and extent of bowel disease, the appearance of adhesions, and the presence of obvious masses; and are helpful as a guide to the diagnosis and in assessing prognosis. However this cannot be relied on in isolation and further investigation is essential. These investigations include a thorough full history, rectal examination, sigmoidoscopy and flexible endoscopy; stool and blood tests including CEA, FIT and fecal genetics are also helpful. We believe that a colonoscopy is usually the study of choice in the diagnosis and staging of colorectal cancer." - Anonymous Online Contributor
"There is a steady increase of colorectal cancer in the United States over the last 40 or 50 years. The average number of people with colorectal cancer per year in the United States has increased from 2.3 in 1960 to 20.8 in 2013. The risk of developing colorectal cancer in the United States increased by nearly four-fold, from 1.4 per 1,000 adults per year in 1960 to 10.5 per 1,000 in 2013. The average number of colorectal cancers in the United States in 2013 was 21.9 per 100,000 adults. There was a 3:1 increase in colorectal cancer incidence in white adults over white males (19." - Anonymous Online Contributor
"Findings from a recent study shows that there is less than 2% residual disease in about 30% of patients who have undergone curative surgery for adenocarcinoma of the colon or rectum. However, this finding means that patients who have tumours that extended to nearby anatomic structures such as the rectum, descending colon or transverse colon may not have a 5-year survival advantage over patients with tumours localized to the colon." - Anonymous Online Contributor
"Colorectal cancer is an uncommon disease. But when it occurs, it can be deadly. Colonoscelis and sigmoidoscopies are the examination of choice if there is a family history of cancer or if there is a suspicion of cancer. But as many as 85% of men undergoing colorectal cancer screenings have no evidence of cancer. Screening colonoscopy is the most important test for colorectal cancer. Colonoscopy is preferable to sigmoidoscopy because of cost, effectiveness, safety, and low complication and mortality rates for colon cancer." - Anonymous Online Contributor
"In the therapeutic context of cancer immunotherapy, immune checkpoint blockade has been shown to be an effective treatment for cancer and this new type of immunotherapy agent illustrates how immunotherapy may be used to treat disease in which the immune system is dysfunctional." - Anonymous Online Contributor
"Most patients with [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) can be cured if detected early, but many patients' colon cancer develops after other types of cancer, such as lung or breast cancer. Colorectal cancer is one of the most difficult types of cancer and there are no complete treatments in a significant proportion of all cases, so the focus should be on improving the detection method of as early as possible so that a complete cure can be obtained. There should be more research on colon cancer detection, treatment and prevention strategies for a better and safe outcome. I had a bad bowel habit for several years. My colonoscopy procedure took time to get comfortable with." - Anonymous Online Contributor
"Results from a recent clinical trial shows, that [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) also runs in the families, similar to other cancer types. In most families colorectal cancer is not a unique cause of colorectal cancer, and further research should concentrate on its familial nature and should identify any known genetic factors for predisposition." - Anonymous Online Contributor
"At present there is disagreement about whether advanced stage [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) which has spread to the liver, lungs or brain is fatal or can be treated and cured, or can lead to long-term survival. However, most doctors agree that a patient with Stage II colorectal cancer is extremely unlikely, in the very least, to have been cured, or to have lived for more than a few years, if all the cancer has not spread to the lymph nodes or other parts of the body." - Anonymous Online Contributor
"This is a simple summary of the survival rates of [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer)s of every type and stage. Survival rates are strongly affected by the stage of the cancer and the age at onset of the disease. Survival rates also increase in individuals diagnosed at earlier stages of disease where the treatment is available. Survival ratios are useful in assessing the difference in outcomes of treatments given in different cohorts, and in comparing treatment outcomes over time." - Anonymous Online Contributor
"Colorectal cancer is the second leading cause of cancer deaths in the developed world. In our cohort of patients, the average age at onset of colorectal cancer was 68; the median age at diagnosis was 61. The median age of death was 65, the median age of death from the colon was 58. The 5-year survival rate was 43%. There appears to be an upturn in the incidence and mortality rates in Australia." - Anonymous Online Contributor